AllianceRx Walgreens Prime to distribute Lundbeck's Vyepti

Lundbeck has named AllianceRx Walgreens Prime, as one of only two specialty pharmacies to distribute Vyepti (eptinezumab-jjmr). The drug is used for the preventive treatment of migraine in adults.

It is the first and only intravenous preventive treatment for migraine.

“We are pleased that Lundbeck chose AllianceRx Walgreens Prime as one of two partners to offer this new migraine medication,” said Tracey James, senior vice president, pharmacy services, at AllianceRx Walgreens Prime. “Because we have a proven track record in supporting other limited distribution drugs with them, we are able to be a true partner that is always willing to collaborate to improve patient outcomes.”